GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01355003
Recruitment Status : Terminated (Merck Sharp & Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing surveillance (PMS) study)
First Posted : May 17, 2011
Last Update Posted : August 13, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This study will collect safety information on the use of GARDASIL™ in the Philippines.

Condition or disease
Papillomavirus Infections

Study Type : Observational
Actual Enrollment : 1080 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
Study Start Date : February 2008
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

All Participants
Participants who were vaccinated with GARDASIL™ by their physician

Primary Outcome Measures :
  1. Number of participants with adverse events following any dose of vaccine [ Time Frame: At least 30 days following any vaccine dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   9 Years to 46 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Data will be collected from physicians who prescribed GARDASIL™ and who voluntarily agree to provide information on their patients. Each physician can provide up to five reports corresponding to five patients.

Inclusion Criteria:

  • Received GARDASIL™

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01355003     History of Changes
Other Study ID Numbers: V501-077
First Posted: May 17, 2011    Key Record Dates
Last Update Posted: August 13, 2015
Last Verified: August 2015

Additional relevant MeSH terms:
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections